Intermediate for Daclatasvir. Daclatasvir (trade name: Daklinza) is a medication used in combination with other medications to treat hepatitis C (HCV). Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A which is critical for HCV viral transcription and translation. Daclatasvir has been approved by the U.S Food and Drug Administration on June 24, 2015.
Product Name: 1H-Imidazole,5,5'-[1,1'-biphenyl]-4,4'-diylbis[2-(2S)-2-pyrrolidinyl-, hydrochloride (1:4)
CAS Number: 1009119-83-8
Molecular Weight:  570.391
Molecular Formula:  C26H32Cl4N6
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.